 |
|
Apomorphine Test for Dopaminergic Responsiveness in Patients With Previously Untreated Parkinson's Disease
Thomas Gasser, MD;
Johannes Schwarz, MD;
Guy Arnold, MD;
Claudia Trenkwalder, MD;
Wolfgang H. Oertel, MD
Arch Neurol. 1992;49(11):1131-1134.
Abstract
| |
• We prospectively examined the predictive value of the apomorphine test for the therapeutic efficacy of sustained oral levodopa treatment in 62 patients with de novo Parkinson syndrome (no additional neurological deficit) who had not previously been treated with dopaminergic medication. Patients received 2 to 5 mg of apomorphine hydrochloride subcutaneously and a subsequent trial of oral levodopa of at least 3 months' duration. In three patients, response to apomorphine could not be evaluated owing to side effects experienced during the test. In the remaining 59 patients, the best predictor of response to oral levodopa was the apomorphine-induced relative decrease in the scores on the motor examination part of the Unified Parkinson Disease Rating Scale (UPDRS). At a cutoff value of 20% improvement in UPDRS scores, the test predicted the response to levodopa correctly in 50 patients (85%). The sensitivity of the test was 90%, specificity 88%. The positive predictive value was 95%. However, seven of 19 apomorphine test—negative patients experienced a good (n=4) or partial (n=3) improvement with levodopa therapy. Thus, the negative predictive value was only 63%. We conclude that response to apomorphine has a high predictive value for response to sustained oral levodopa treatment in most previously untreated patients, but a negative test should not preclude an adequate trial of oral levodopa.
Author Affiliations
From the Department of Neurology (Movement Disorder Outpatient Clinic), University Hospital Grosshadern, Ludwig-Maximilians University Munich, Federal Republic of Germany.
Footnotes
Accepted for publication May 12, 1992.
Reprint requests to Neurologische Klinik, Klinikum Groβhadern, Ludwig-Maximilians-Universität München, Postfach 70 12 60, Marchionninistraβe 15, 8000 Munchen 70, Germany (Dr Gasser).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The role of levodopa in the management of dementia with Lewy bodies
Molloy et al.
J. Neurol. Neurosurg. Psychiatry 2005;76:1200-1203.
ABSTRACT
| FULL TEXT
Practical considerations in the use of apomorphine injectable
Bowron
Neurology 2004;62:S32-S36.
ABSTRACT
| FULL TEXT
L -Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism
Kaiser et al.
Neurology 2003;60:1750-1755.
ABSTRACT
| FULL TEXT
Increased Growth Hormone Response to Apomorphine in Parkinson Disease Compared With Multiple System Atrophy
Friess et al.
Arch Neurol 2001;58:241-246.
ABSTRACT
| FULL TEXT
Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease
Clarke and Davies
J. Neurol. Neurosurg. Psychiatry 2000;69:590-594.
ABSTRACT
| FULL TEXT
Hallucinations, REM sleep, and Parkinson's disease: A medical hypothesis
Arnulf et al.
Neurology 2000;55:281-288.
ABSTRACT
| FULL TEXT
Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease
Kompoliti et al.
Neurology 2000;54:458-458.
ABSTRACT
| FULL TEXT
Parkinson's disease and tumour in the supplementary motor area: a re-evaluation
KUPSCH et al.
J. Neurol. Neurosurg. Psychiatry 1997;63:811-812.
FULL TEXT
|
